Creat takeover of Biotest closed

  • Transfer of tendered shares completed
  • Majority shareholding (approx. 90% of Biotest AG’s ordinary shares and voting share capital) of Creat in Biotest

Dreieich, 31 January 2018. On 19 January 2018 Biotest AG disclosed that the last remaining condition has been met for the takeover offer by Tiancheng (Germany) Pharmaceutical Holdings AG, the acquisition company of the Creat Group Corporation. Thus the unsolicited takeover offer announced on 18 May 2017 for the shares of Biotest AG became effective and could be settled.
The offer by Tiancheng (Germany) Pharmaceutical Holdings AG and payment of the purchase price to the custodial bank of the accepting Biotest shareholders was settled promptly and, as described in section 13.5 of the offer document.
Tiancheng (Germany) Pharmaceutical Holdings AG, an indirect controlled subsidiary of Creat Group Corporation, a company organized and existing under the laws of the People’s Republic of China, hereby holds a majority interest (approx. 90% of Biotest AG’s ordinary shares and voting share capital) in Biotest AG.

Our product range

Our development pipeline

Phase 1

Phase 2

Phase 3

Approval

Launch

IgG Next Generation (BT-595) - Primary Immune Deficiency (PID)
IgG Next Generation (BT-595) - Idiopathic Thrombocytopenic Purpura (ITP)
Fibrinogen (BT-524) - Congenital fibrinogen deficiency
Fibrinogen (BT-524) - Acquired Fibrinogen Deficiency
Cytotect 70 (BT-084) - Congenital CMV infection prophylaxis
Trimodulin (BT-086) - Severe community acquired pneumonia
(BT-063) - Systemic lupus erythematosus
Indatuximab Ravtansine (BT-062) - Multiple myeloma
Indatuximab Ravtansine* (BT-062) - Solid tumors
Tregalizumab (BT-061) - other diseases

Pipeline

Overview of all projects and their status from the therapy areas Haematology, Immunology and Intensive care medicine

Further information

Press releases

Biotest increases revenues in the first quarter 2018 by...

15.05.2018,

PRESS RELEASEBiotest increases revenues in the first quarter 2018 by 34%- Guidance confirmed- Q1 EBIT totalled to EUR -3.0 million after EUR-33.2 million in Q1 2017Dreieich, 15 May 2018. In the first ... [More]

Biotest AG: Annual general meeting approves payout of d...

15.05.2018,

PRESS RELEASEBiotest AG: Annual general meeting approves payout of dividend- Dividend payout of EUR 0.04 per preference shareDreieich/ Frankfurt a. M., 15 May 2018. At the annual general meeting (AGM) ... [More]

New data from Biotest's monoclonal antibody-drug-conjug...

03.05.2018,

PRESS RELEASENew data from Biotest's monoclonal antibody-drug-conjugate (ADC) BT-062 in the therapy of solid tumors- Good tolerability and signs of efficacy in phase I/IIa clinical study- Very good ef ... [More]

Biotest reaches 2017 profit guidance

22.03.2018,

PRESS RELEASEBiotest reaches 2017 profit guidance- Adjusted EBIT stable- Five new plasmapheresis centres opened in Europe- Biotest Next Level: building acceptance obtained and successful "Good Manufac ... [More]

First patient with acquired fibrinogen deficiency treat...

15.03.2018,

PRESS RELEASEFirst patient with acquired fibrinogen deficiency treated in clinical phase III study of Biotest AG - Important milestone reached in the clinical development programme of fibrinogen conce ... [More]

Biotest supports a large international registry study t...

13.03.2018,

PRESS RELEASE Biotest supports a large international registry study to record data on use of Pentaglobin(R) in patients with severe bacterial infections- High medical need due to high mortality a ... [More]

Biotest reaches FY 2017 EBIT guidance

27.02.2018,

Ad-hoc RELEASEAnnouncement according to Article 17 European Market Abuse Regulation (MAR)Biotest reaches FY 2017 EBIT guidanceDreieich, 27 February 2018. According to preliminary and unaudited figures ... [More]

Tiancheng intends to enter into a domination and profit...

08.02.2018,

Ad-hoc RELEASEAnnouncement according to Article 17 European Market Abuse Regulation (MAR)Tiancheng intends to enter into a domination and profit and loss transfer agreement with Biotest AGDreieich, 8 ... [More]

Release according to Article 40, Section 1 of the WpHG ...

02.02.2018,

Notification of Major Holdings1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification X Acquisition/disposal of shares with voting rights   Acquisit ... [More]

Release according to Article 40, Section 1 of the WpHG ...

01.02.2018,

Notification of Major Holdings1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification X Acquisition/disposal of shares with voting rights   Acquisit ... [More]

Creat takeover of Biotest closed

31.01.2018,

/PRESS RELEASE Creat takeover of Biotest closed- Transfer of tendered shares completed- Majority shareholding (approx. 90% of Biotest AG's ordinary shares and voting share capital) of Creat in Bi ... [More]

Biotest AG opens second plasma collection centre in Cze...

24.01.2018,

/PRESS RELEASEBiotest AG opens second plasma collection centre in Czech Republic- 19 plasma collection centres in Europe to ensure long-term plasma supplyDreieich, 24 January 2018. Biotest received an ... [More]

All conditions met for Creat takeover of Biotest

19.01.2018,

/Ad-hoc RELEASEAnnouncement according to Article 17 European Market Abuse Regulation (MAR)All conditions met for Creat takeover of BiotestDreieich, 19. January 2018. Biotest AG disclosed today that fo ... [More]

Release according to Article 40, Section 1 of the WpHG ...

11.01.2018,

Notification of Major Holdings1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification X Acquisition/disposal of shares with voting rights   Acquisit ... [More]

Trimodulin: concept for phase III study successfully co...

20.12.2017,

/PRESS RELEASETrimodulin: concept for phase III study successfully coordinated with the authorities- Clinical concept of the Phase III study is supported by the regulatory authorities- Optimized produ ... [More]

Preliminary announcement of the publication of financia...

06.12.2017,

Biotest AG hereby announces that the following financial reports shall be disclosed : Report: Annual financial report Date of disclosure / German: March 22, 2018 Date of disclosure / English: March ... [More]

Preliminary announcement of the publication of quarterl...

06.12.2017,

Biotest AG hereby announces that the following financial reports shall be disclosed : Report: Quarterly financial report within the 1st half-year (Q1) Date of disclosure / German: May 15, 2018 Date ... [More]

Biotest supports a randomized multicenter controlled tr...

05.12.2017,

/PRESS RELEASEBiotest supports a randomized multicenter controlled trial in peritonitis (PEPPER trial) with Pentaglobin(R) lead by Aachen University- Trial investigates personalized treatment approach ... [More]

Biotest generates revenues of EUR 377.8 million in the ...

14.11.2017,

PRESS RELEASEBiotest generates revenues of EUR 377.8 million in the first nine months 2017- Successful regulatory inspection and approval of Biotest Next Level in August- Paul-Ehrlich Institute approv ... [More]

Tender Offer by Tiancheng (Germany) Pharmaceutical Hold...

07.11.2017,

/Ad-hoc RELEASEAnnouncement according to Article 17 European Market Abuse Regulation (MAR)Tender Offer by Tiancheng (Germany) Pharmaceutical Holdings AG / Tiancheng withdrawal of application of transa ... [More]

Careers

Careers

Passionate to help us save lives?

Investor Relations

Investor Relations

The primary objective of our Investor Relations activities is an open and up-to-date dialogue with the financial community.